Comparison · NCT01544309-sae
Atorvastatin Administration Group vs Rosuvastatin Administration Group: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Atorvastatin Administration Group vs Rosuvastatin Administration Group: serious adverse events. Trial comparisons, record NCT01544309-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01544309-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0277 | 0.0166 | 0.0459 | wilson | |
| Risk in group 2 | 0.0368 | 0.0237 | 0.0568 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00915 | -0.032 | 0.0133 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.751 | 0.381 | 1.48 | log | |
| Odds ratio, group 1 over group 2 | 0.744 | 0.369 | 1.5 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Atorvastatin Administration Group than on Rosuvastatin Administration Group | 109 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Atorvastatin Administration Group | Atorvastatin: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the ATV dose of 20 mg.) | 14 | 506 | EG000 |
| Group 2 | Rosuvastatin Administration Group | Rosuvastatin: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the RSV dose of 10 mg.) | 19 | 516 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- At the start of the treatment, 3, 6, and 12 months after administration
Source ClinicalTrials.gov
Trial
- Title
- LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
- NCT number
- NCT01544309
- Phases
- NA
- Conditions
- Hypercholesterolemia With Concomitant Type 2 Diabetes
- Interventions
- Atorvastatin, Rosuvastatin
- Lead sponsor
- Listen Trial Group
- Results first posted
- 2015-03-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01544309?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01544309-sae